This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
In May, the FDA approved erenumab, the first calcitonin gene-related peptide (CGRP) inhibitor for the prevention of migraine in adults. Since then, 2 other CGRP inhibitors have gained approval, providing a new class of drugs for those who suffer from migraine.
This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss the emerging therapy for the condition, which affects 39 million people in the United States.
Log in to listen to the podcast.
Listen above or through one of these podcast services:
iTunes: http://apple.co/2eYWTss
TuneIn: http://bit.ly/2gv7iwj
Stitcher: http://bit.ly/2gCqtFg
Read more:
FDA Approves Erenumab, First CGRP Inhibitor for Prevention of Migraine
Erenumab for Migraine Is Cost-Effective, but Long-Term Harms Remain Unclear
ICER Releases Final Evidence Report on Efficacy, Cost Effectiveness of CGRP Inhibitors for Migraine
Migraine Survey Highlights Significant Lack of Awareness of CGRP Inhibitors
CGRP Inhibitor Erenumab Shows Efficacy in Migraine Within 1 Week
A coverage with evidence development (CED) study demonstrated significant and clinically meaningful benefits in patients with migraine treated with remote electrical neuromodulation (REN). Health plans should support clinicians’ REN prescriptions by ensuring adequate coverage.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Care for Migraine Insufficient in Germany, Online Survey Finds
March 25th 2022An online survey of migraineurs in Germany aimed to evaluate their most pressing unmet needs, with data collected on socioeconomic background, medical care experience, acute medication use, and migraine prophylaxis use and experience.
Read More